Biogen Inc. Stock Reacts After Quarterly Figures and Alzheimer Partnership with Lilly

{
  "signal_id": "0e7535a2-88bc-1c66-cb1a-9a7c8911526b",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-07-23T17:15:25+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/die-biogen-inc-aktie-reagiert-nach-quartalszahlen-und/69854936",
    "title": "Biogen Inc. Stock Reacts After Quarterly Figures and Alzheimer Partnership with Lilly - Ad-hoc-news.de",
    "excerpt": "Biogen Inc. (ISIN US09062X1037) remains an exciting value for investors because the Biogen Inc. stock, after the recently published business figures and the strategic Alzheimer's partnership with Eli Lilly, depends primarily on the progress of new active ingredients and the earnings profile of the core business. In the 2023 fiscal year, Biogen achieved a revenue of approximately 9.8 billion US dollars, according to company information, while the adjusted earnings per share (Non-GAAP EPS) was around 14 US dollars, thus slightly below the previous year's level. The cooperation with Lilly concerning the antibody Leqembi and other Alzheimer's therapies shifts the company's focus more strongly towards neurodegeneration, which is likely to be reflected in the Biogen Inc. stock price in the medium term.\nThe recently presented figures for 2023 and the preceding reporting period illustrate the restructuring of the business model. According to company information, Biogen achieved a revenue of approximately 10.2 billion US dollars in fiscal year 2022, before revenue decreased to about 9.8 billion US dollars in fiscal year 2023, which corresponds to a decline of approximately 4 percent. The decline primarily results from the decrease in sales of older multiple sclerosis medications, whose sales are burdened by competition and generics, while newer products in the neurology and rare...",
    "product": "Leqembi",
    "summary": "Biogen Inc. is in a strategic partnership with Eli Lilly to develop and market new treatment options for Alzheimer's, including the monoclonal antibody Leqembi.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2702773_1920_1080.webp",
    "confidence": 0.9,
    "product_data": {
      "name": "Leqembi",
      "full_text": "the monoclonal antibody Leqembi",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-07-23T17:15:25Z",
    "article_sentence": "For several years, Biogen has been working closely with Lilly to develop and market new treatment options for patients with early Alzheimer's dementia.",
    "related_company_name": "Eli Lilly",
    "related_company_domain": "lilly.com"
  }
}

curl https://signals.autobound.ai/v1/signals/0e7535a2-88bc-1c66-cb1a-9a7c8911526b \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"biogen.com","limit":20}'